Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001683168-24-007622
Filing Date
2024-11-05
Accepted
2024-11-05 16:05:21
Documents
59
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q FOR SEPT 2024 sunshine_i10q-093024.htm   iXBRL 10-Q 734041
2 CERTIFICATION sunshine_ex3101.htm EX-31.1 12987
3 CERTIFICATION sunshine_ex3102.htm EX-31.2 12887
4 CERTIFICATION sunshine_ex3201.htm EX-32.1 5917
5 GRAPHIC image_001.jpg GRAPHIC 6153
  Complete submission text file 0001683168-24-007622.txt   4016664

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE sbfm-20240930.xsd EX-101.SCH 32221
7 XBRL CALCULATION FILE sbfm-20240930_cal.xml EX-101.CAL 45577
8 XBRL DEFINITION FILE sbfm-20240930_def.xml EX-101.DEF 158706
9 XBRL LABEL FILE sbfm-20240930_lab.xml EX-101.LAB 290550
10 XBRL PRESENTATION FILE sbfm-20240930_pre.xml EX-101.PRE 251065
61 EXTRACTED XBRL INSTANCE DOCUMENT sunshine_i10q-093024_htm.xml XML 410703
Mailing Address 333 LAS OLAS WAY CU4 SUITE 433 FORT LAUDERDALE FL 33301
Business Address 333 LAS OLAS WAY CU4 SUITE 433 FORT LAUDERDALE FL 33301 954-515-0810
Sunshine Biopharma Inc. (Filer) CIK: 0001402328 (see all company filings)

EIN.: 205566275 | State of Incorp.: CO | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41282 | Film No.: 241427418
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)